NEW YORK (GenomeWeb News) – Cellectis and Genoway today announced a sublicensing deal covering Cellectis' homologous recombination technology.

The deal makes animal model firm Genoway the exclusive provider of the technology for research applications in genetically modified rodents. Cellectis retains rights to it for all other applications, such as bioproduction and therapeutics. Cellectis licenses the technology from Institut Pasteur.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.